Peripheral Vascular Disease (PVD) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Job Strain Linked to Increase in Risk for PAD Hospitalization
TUESDAY, April 28, 2020 -- Job strain is associated with a 1.41-fold increase in the average risk for peripheral artery disease (PAD) hospitalization, according to a study published online April 28 in the Journal of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2020 Category: Pharmaceuticals Source Type: news
Job Strain May Boost Odds of Serious Artery Disease
TUESDAY, April 28, 2020 -- Work stress may increase your risk for ending up in the hospital with peripheral artery disease, a new study suggests.
Peripheral artery disease (PAD) occurs when cholesterol or other fatty substances accumulate in blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 28, 2020 Category: General Medicine Source Type: news
On-the-job stress raises risk for peripheral artery disease, study finds
Stress on the job may increase a person's risk for peripheral artery disease, according a study published Tuesday in the Journal of the American Heart Association. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 28, 2020 Category: Consumer Health News Source Type: news
Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, C...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
COVID-19 Business Updates Provide Some Clarity
The unknowns still outnumber the knowns, but recent business updates provide some clarity around how the medical device industry is fairing during the COVID-19 pandemic. First and foremost, it is clear that companies are hurting in the areas of elective procedures, which are being deferred. But there may be some silver linings hidden amongst the bad news.
Needham & Co. medtech analyst Mike Matson estimates that medical device sales across the industry will continue to drop by an average of 40% to 50% until the economy begins to reopen and hospitals start to resume elective procedures.
Matson's e...
Source: MDDI - April 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news
Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS
The new vascular low dose of rivaroxaban has gotten off to a slow start, but these new subgroup results may stimulate use in patients with diabetes and stable coronary or peripheral artery disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
28.03.20: Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularizationThe only clinical outcome study to demonstrate the benefits of a combined antithrombotic and anti-platelet therapy in these vulnerable patients who currently have limited treatment options / Risk of acute limb ischemia was significantly reduced by 33% in these patients compared to those receiving aspirin alone / There was no significant increase in TIMI major bleeding, the principal safety outcome of the trialmehr ... (Source...
Source: Bayer IR Newsfeed: Events - March 27, 2020 Category: Pharmaceuticals Source Type: news
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto ™ ) Phase III studies (for specialized target groups only)
The VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate Bayer’s ongoing commitment to the treatment of cardiovascular disease (Source: Bayer Company News)
Source: Bayer Company News - March 20, 2020 Category: Pharmaceuticals Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
20.03.20: Not intended for U.S. and UK Media -
American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual):
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto™) Phase III studiesThe VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate...
Source: Bayer IR Newsfeed: Events - March 19, 2020 Category: Pharmaceuticals Source Type: news
Study maps landmarks of peripheral artery disease to guide treatment development
(University of Illinois at Urbana-Champaign, News Bureau) Novel biomedical advances that show promise in the lab often fall short in clinical trials. For researchers studying peripheral artery disease, this is made more difficult by a lack of standardized metrics for what recovery looks like. A new study from University of Illinois at Urbana-Champaign researchers identifies major landmarks of PAD recovery, creating signposts for researchers seeking to understand the disease and develop treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 2, 2020 Category: International Medicine & Public Health Source Type: news
Cocoa a Novel Rx for Peripheral Artery Disease? Cocoa a Novel Rx for Peripheral Artery Disease?
Results of a pilot randomized trial suggest a beverage with>85% cacao may also improve symptoms of PAD, including 6-minute walk and perfusion in the legs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 26, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Cocoa Consumption May Improve Walking Performance in PAD
FRIDAY, Feb. 14, 2020 -- Cocoa consumption may improve walking performance in individuals with peripheral artery disease (PAD), according to a study published online Feb. 14 in Circulation Research.
Mary M. McDermott, M.D., from the Northwestern... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2020 Category: Pharmaceuticals Source Type: news
